2011 - IPITA - Prague


This page contains exclusive content for the member of the following sections: TTS, IPITA. Log in to view.

Parallel session 2 – Open oral presentations Topic: Results of clinical autologous and allogeneic islet transplantation

2.4 - Factors of islet transplant success: results from the Collaborative Islet Transplant Registry 1999-2010

Presenter: M., Rickels, Philadelphia, USA
Authors: M. Rickels, F.B. Barton, R. Alejandro, F. Pattou, T. Berney, P. Senior, S. Messinger


Factors of islet transplant success: results from the Collaborative Islet Transplant Registry 1999-2010

M. Rickels1, F.B. Barton2, R. Alejandro3, F. Pattou4, T. Berney5, P. Senior6, S. Messinger3
1 University of Pennsylvania School of Medicine, Philadelphia, PA, USA; 2 The EMMES Corporation, Rockville, MD, USA; 3 University of Miami, Miami, FL, USA; 4 Lille University, Lille, France; 5 Geneva University, Geneva, Switzerland; 6 University of Alberta, Edmonton, Canada

Objective: Identifying factors that predict successful outcomes of allogeneic islet transplantation can guide patient selection and management. Data from the Collaborative Islet Transplant Registry (CITR), was used to identify factors of successful outcomes.

Methods:. As of November 2010, 408 islet alone and 73 islet-after-kidney or simultaneous-islet-kidney with 1-6 infusions in 1999-2009 and >1 year follow-up were analyzed by Cox proportional hazards for all available patient, donor, islet and immunosuppression factors on retention of insulin independence >14 days (II), and sustained C-peptide levels >0.3 ng/mL, multivariately at p<0.15.

Results: The favorable factors for II yield an estimated 65% retaining II 5 years post last infusion, compared with 20% of those without (Table 1 and Figure 1). For retention of C-peptide>0.3 ng/mL, favorable factors can effect an 85% rate of C-peptide retention at 5 years (Table 2 and Figure 2) compared to nearly 0% with unfavorable factors.

Conclusions: Patient characteristic selection and carefully selected immunosuppression can effectuate remarkable improvements in outcomes of islet transplantation. Some factors that may favorable for one outcome may not be favorable for others.

Factors

Hazard
Ratio

p

Era (99-03,04-06,07-09)

0.688

0.001

Age (<35, 35-50, >50)

1.401

0.028

ITA (0) vs IAK (1)

1.636

0.07

+TCell depletion +TNF-a blockade

2.915

0.11

Table 1. Final Cox model for retention of insulin independence post last infusion

ITA = islet transplant alone

IAK = islet after kidney / simultaneous islet-kidney

Figure 1. Retention of II (95%CI) with favorable factors (see Table 1) vs. unfavorable factors.

Factors

Hazard
Ratio

p

Baseline insulin/day

(<25, 25-43,>43)

1.453

0.0046

Culture time (<1h, 1-15, >15)

0.714

0.0017

TNF-a blockade (0=N 1=Y)

0.611

0.0527

Calcineurin inhibitor (0=N 1=Y)

0.343

0.0025

Table 2. Final Cox model for retention of C-peptide>0.3 ng/mL

Figure 2. Retention of C-peptide>0.3 ng/mL (95% CI) with favorable factors (see Table 2) vs. unfavorable factors.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada